• Profile
Close

The CIRCULATE trial: Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation (AIO-KRK-0217)

Clinical Colorectal Cancer Sep 19, 2021

Folprecht G, Reinacher-Schick A, Weitz J, et al. - The CIRCULATE trial may establish circulating tumor (ct)DNA for adjuvant treatment decision in stage II colon cancer – and with the secondary aims – promote a ctDNA guided follow up in colon cancer stage II and beyond.

  • In individuals with early stage and resected colorectal cancer, ctDNA is a prognostic biomarker of recurrence.

  • The CIRCULATE trial looks at the prognostic value of ctDNA for adjuvant treatment in stage II colon cancer.

  • A total of 231 patients with detectable ctDNA (ctDNApos) after resection are randomized 2:1 to chemotherapy or to control (follow-up).

  • Patients with no detectable ctDNA (about 2,079 patients) are randomly assigned 1:4 to the control or off-study groups.

  • Disease-free survival is the primary endpoint.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay